

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

BUTAMAX(TM) ADVANCED BIOFUELS
LLC

Plaintiff,

v.

GEVO, INC.

Defendant.

12 - 298

C.A. No. _____

JURY TRIAL DEMANDED

COMPLAINT

Plaintiff Butamax™ Advanced Biofuels LLC (“Butamax”), by its attorneys, for its Complaint against Defendant Gevo, Inc. (“Gevo”), alleges as follows:

THE PARTIES

1. Butamax is a limited liability company organized and existing under the laws of the state of Delaware, with its principal place of business in Wilmington, Delaware. Butamax has developed methods of making isobutanol, an advanced biofuel that will provide improved options for increasing energy supplies and facilitate the transition to renewable transportation fuels which lower overall greenhouse gas emissions. Isobutanol can also be used as a feedstock chemical in the production of various plastics, fibers and other products.

2. Butamax has developed novel methods of producing isobutanol with recombinant microorganisms. In particular, Butamax has invented enzymes that can be used to efficiently catalyze chemical reactions leading to isobutanol in genetically engineered microorganisms.

3. On information and belief, Gevo is a corporation organized and existing under the laws of the state of Delaware, with its principal place of business in Englewood, Colorado.

FILED
CLERK, U.S. DISTRICT COURT
DISTRICT OF DELAWARE
2012 MAR 12 AM 10:38

JURISDICTION AND VENUE

4. This action arises under the Declaratory Judgment Act and the Patent Statute of the United States of America, Titles 28 and 35 of the United States Code. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

5. On information and belief, this Court has personal jurisdiction over Gevo because it is a Delaware corporation with a registered Delaware agent and has purposefully availed itself of the benefits and protections of this state.

6. Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b) and (c) and 1400(b).

BACKGROUND

7. United States Patent No. 8,129,162 (“the ‘162 patent”) entitled KETOL-ACID REDUCTOISOMERASE USING NADH, duly and legally issued on March 6, 2012 to inventors Yougen Li, Der-Ing Liao, Mark J. Nelson and Daniel P. O’Keefe. The ‘162 patent is assigned to Butamax. Butamax owns the ‘162 patent and has owned the patent since it issued.

8. The ‘162 patent discloses and claims certain recombinant mutant ketol-acid reductoisomerase enzymes. Ketol-acid reductoisomerase enzymes are commonly abbreviated as “KARI” enzymes. A true and correct copy of the ‘162 patent is attached hereto as Exhibit A.

9. The ‘162 patent provides KARI enzymes that function more effectively in microbial systems designed to produce isobutanol.

10. On information and belief, Gevo currently makes and uses KARI enzymes that embody the invention of the ‘162 patent.

11. On information and belief, Gevo currently makes and uses recombinant microorganisms comprising recombinant mutant KARI enzymes that embody the invention of the '162 patent, in order to produce isobutanol.

12. On information and belief, Gevo's U.S. Patent 8,097,440 provides the sequences of recombinant mutant KARI enzymes that Gevo makes and uses.

13. For example, on information and belief, SEQ ID NO 44 of Gevo's U.S. Patent 8,097,440, is an amino acid sequence of a recombinant mutant KARI enzyme that Gevo makes and uses to produce isobutanol.

14. During a recent earnings conference call, Gevo stated that the enzymes of Gevo's U.S. Patent 8,097,440 were genetically engineered for purposes of producing isobutanol on a commercial basis.

15. On information and belief, Gevo owns an ethanol production facility and plans this year to complete retrofitting this facility to produce isobutanol commercially using its recombinant mutant KARI enzymes. Gevo has entered into contracts with third parties to supply them with isobutanol produced from this facility. Gevo also plans to purchase additional facilities for the commercial production of isobutanol using its recombinant mutant KARI enzymes.

16. On information and belief, at least Gevo's making and using of such KARI enzymes and/or its inducement of others to make and use such KARI enzymes infringes the '162 patent.

COUNT I - PATENT INFRINGEMENT

17. Each of the preceding paragraphs, 1-16 is incorporated as if fully set forth herein.

18. On information and belief, Gevo directly and/or indirectly infringes and will continually infringe, either literally or by the doctrine of equivalents, one or more claims of the '162 patent, pursuant to 35 U.S.C. § 271.

19. On information and belief, Gevo's infringement of the '162 patent will continue, unless enjoined by this Court. Gevo's infringement causes harm to Butamax. Thus, there is a real and actual controversy between Butamax and Gevo.

REQUEST FOR RELIEF

WHEREFORE, Plaintiff respectfully requests the following relief:

(a) That a declaratory judgment be entered declaring that Gevo infringes one or more claims of the '162 patent and that Gevo's making and using of its recombinant mutant KARI enzymes, and/or its inducement of others to make and use recombinant mutant KARI enzymes are acts of infringement of one or more claims of the '162 patent;

(b) That Gevo and its officers, employees, agents, attorneys, affiliates, successors, assigns and others acting in privity or concert with it be preliminarily and permanently enjoined from making and using recombinant mutant KARI enzymes claimed by the '162 patent or inducing others to produce recombinant mutant KARI enzymes claimed by the '162 patent;

(c) That judgment be entered awarding Plaintiff damages resulting from Gevo's infringement in an amount no less than a reasonable royalty, and that such amount be multiplied based on Gevo's continuing willful and deliberate infringement, pursuant to 35 U.S.C. § 285;

(d) That this case be deemed exceptional and attorneys' fees be awarded pursuant to 35 U.S.C. § 285;

(e) That interest, costs and expenses be awarded in favor of Butamax;

(f) That this Court order such other and further relief as the Court may deem just and proper.

JURY DEMAND

Butamax hereby demands trial by jury in this action on all issues so triable.

Dated: March 12, 2012.

POTTER ANDERSON & CORROON LLP

OF COUNSEL:

Leora Ben-Ami
Christopher T. Jagoe
Hank Heckel
KAYE SCHOLER LLP
425 Park Avenue
New York, NY 10022
Tel: (212) 836-8000

Dated: March 12, 2012
1050665 / 36429

By: /s/ Richard L. Horwitz
Richard L. Horwitz (#2246)
David E. Moore (#3983)
Hercules Plaza, 6th Floor
1313 N. Market Street
Wilmington, DE 19801
Tel: (302) 984-6000
rhorwitz@potteranderson.com
dmoore@potteranderson.com

Attorneys for Plaintiff
Butamax™ Advanced Biofuels LLC